<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357899</url>
  </required_header>
  <id_info>
    <org_study_id>33_20B</org_study_id>
    <nct_id>NCT04357899</nct_id>
  </id_info>
  <brief_title>Stroke Research Consortium in Northern Bavaria (STAMINA)</brief_title>
  <acronym>STAMINA</acronym>
  <official_title>Stroke Research Consortium in Northern Bavaria - STAMINA, a Multicenter Longitudinal Cohort Study on Ischemic Stroke Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Each year, approximately 15 million people suffer a stroke worldwide of which 80% are due to&#xD;
      ischemic cerebral infarction. Based on the results of randomized controlled trials, treatment&#xD;
      options and patient outcomes in acute ischemic stroke have dramatically improved in recent&#xD;
      years. However, these advances in thrombolysis and endovascular therapy need to be&#xD;
      established outside controlled trials to optimize stroke management, treatment procedures,&#xD;
      patient selection and inter-hospital transfer in clinical practice. This multicenter&#xD;
      longitudinal cohort study is based on a large stroke care network in Northern Bavaria,&#xD;
      Germany (region of more than 3.5 million inhabitants) to evaluate and improve treatment in&#xD;
      ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: This multicenter longitudinal cohort study will include ischemic stroke patients&#xD;
      treated within a telemedical stroke care network and patients transferred to tertiary stroke&#xD;
      centers for treatment procedures from hospitals outside the telemedical network. Individual&#xD;
      patient data are available from two tertiary stroke centers and 24 primary and secondary&#xD;
      stroke facilities in Northern Bavaria, Germany. Patients with ischemic stroke transferred to&#xD;
      the tertiary stroke centers for treatment procedures - i.e. endovascular therapy or&#xD;
      thrombolysis in stroke with an unknown time of onset - and all stroke patients with either&#xD;
      large vessel occlusion (LVO) and/or thrombolysis therapy admitted to the University Hospital&#xD;
      Erlangen will be integrated from institutional prospective stroke registries. Consecutive&#xD;
      patients admitted between January 2006 and December 2019 will be included, an estimated total&#xD;
      number of more than 3000 ischemic stroke patients - approximately 1000 patients with LVO&#xD;
      receiving endovascular therapy, 1000 patients with LVO not receiving endovascular therapy and&#xD;
      1000 patients without LVO receiving thrombolysis therapy.&#xD;
&#xD;
      Demographic and clinical data including medical history, medication and laboratory results&#xD;
      will be obtained by review of medical charts, institutional databases or prospective&#xD;
      registries, supplemented by structured interviews on follow-up information or by review of&#xD;
      all available medical records. In detail the following parameters will be evaluated: prior&#xD;
      medical history (e.g. comorbidities, premorbid functional status, medication), admission&#xD;
      status (e.g. NIHSS, GCS, body temperature, arterial blood pressure), cerebral imaging&#xD;
      parameters (e.g. Alberta Stroke Program Early CT score [ASPECTS], perfusion volumes, mismatch&#xD;
      and collateral status on admission imaging, final infarct volume on follow-up imaging),&#xD;
      treatment procedures (e.g. intravenous thrombolysis, endovascular therapy, decompressive&#xD;
      surgery), time intervals (e.g. symptom onset or last seen normal until admission, imaging,&#xD;
      thrombolysis, groin puncture, recanalization), complications (e.g. hemorrhagic&#xD;
      transformation, arterial dissection, distant ischemic stroke), laboratory parameters,&#xD;
      clinical and diagnostic follow-up (e.g. neurological status, blood pressure, vascular&#xD;
      ultrasound), stroke etiology, secondary prevention (e.g. lipid lowering medication,&#xD;
      antiplatelet therapy, anticoagulation) and clinical outcomes (e.g. mortality, modified Rankin&#xD;
      Scale).&#xD;
&#xD;
      Ethics Approval: The study was approved by the Institutional Review Board of the&#xD;
      Friedrich-Alexander-Universität Erlangen-Nürnberg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2006</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Outcome (modified Rankin Scale 0-6)</measure>
    <time_frame>at day 90</time_frame>
    <description>The Distribution of Scores on the modified Rankin Scale (mRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Independence (modified Rankin Scale 0-2)</measure>
    <time_frame>at day 90</time_frame>
    <description>Proportion of participants with functional independence (mRS 0-2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Favorable Outcome (modified Rankin Scale 0-1)</measure>
    <time_frame>at day 90</time_frame>
    <description>Proportion of participants with favorable outcome (mRS 0-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infarct volume</measure>
    <time_frame>at day 5 (±2)</time_frame>
    <description>Infarct volume on CT or diffusion-weighted MRI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion growth volume</measure>
    <time_frame>at day 5 (±2)</time_frame>
    <description>Lesion growth volume between ischemic core on baseline imaging and infarkt volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intracranial hemorrhage</measure>
    <time_frame>at 24 (±6) hours</time_frame>
    <description>Rate of intracranial hemorrhage defined according to different criteria (ECASS II, SITS-MOST, NINDS or Parenchymal hemorrhage Type 2) on the 24 hour scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recanalization Rates</measure>
    <time_frame>at 24 (±6) hours</time_frame>
    <description>Recanalization of the primary arterial occlusive lesion (based on ultrasound, clinical and radiological assessment) at 24-hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>at 90 days</time_frame>
    <description>All cause mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>procedure</time_frame>
    <description>Time from groin puncture to first recanalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Door-to-groin puncture time</measure>
    <time_frame>until 24 hours after admission to the tertiary stroke center or until hospital discharge, whichever came first</time_frame>
    <description>Time from arrival at the tertiary stroke center to groin puncture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Door-to-needle time</measure>
    <time_frame>until 24 hours after admission to the tertiary stroke center or until hospital discharge, whichever came first</time_frame>
    <description>Time from hospital arrival to IVT administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom-to-door time</measure>
    <time_frame>until 24 hours after admission to the tertiary stroke center or until hospital discharge, whichever came first</time_frame>
    <description>Time from symptom onset to arrival at the first hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interhospital transfer time</measure>
    <time_frame>until 24 hours after admission to the tertiary stroke center or until hospital discharge, whichever came first</time_frame>
    <description>Time from arrival at the first hospital to arrival at the tertiary stroke center</description>
  </secondary_outcome>
  <enrollment type="Actual">3769</enrollment>
  <condition>Ischemic Stroke</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thrombolysis therapy</intervention_name>
    <other_name>thrombolytic drugs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endovascular therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>decompressive surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>multimodal imaging in acute ischemic stroke</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transfer of acute stroke patients to tertiary stroke centers</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>initiation of antiplatelets, oral anticoagulation and lipid lowering drugs for secondary prevention</intervention_name>
    <other_name>antithrombotic oder lipid lowering drugs</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Ischemic stroke patients treated within a stroke care network in Northern Bavaria, Germany.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke&#xD;
&#xD;
          -  Presence of large vessel occlusion (as evidenced by CTA, MRA or DSA) and/or&#xD;
             intravenous thrombolysis therapy applied&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Schwab</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Neurology, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnd Dörfler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Neuroradiology, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernd Kallmünzer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Neurology, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Engelhorn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Neuroradiology, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurologische Klinik, Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Erlangen-Nürnberg Medical School</investigator_affiliation>
    <investigator_full_name>Bernd Kallmünzer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Thrombolysis</keyword>
  <keyword>Mechanical thrombectomy</keyword>
  <keyword>Endovascular procedure</keyword>
  <keyword>Stroke</keyword>
  <keyword>Cerebrovascular Disorders</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Brain Ischemia</keyword>
  <keyword>Cerebral Infarction</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Tissue Plasminogen Activator</keyword>
  <keyword>Fibrinolytic Agents</keyword>
  <keyword>Fibrin Modulating Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypolipidemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Because of local ethics committees restrictions the final decision upon release of the raw data has not been made.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

